Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.

Autor: Garcia-Aguilar J; Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: garciaaj@mskcc.org., Renfro LA; Mayo Clinic, Rochester, MN, USA., Chow OS; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shi Q; Mayo Clinic, Rochester, MN, USA., Carrero XW; Mayo Clinic, Rochester, MN, USA., Lynn PB; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Thomas CR Jr; Oregon Health and Science University, Portland, OR, USA., Chan E; Vanderbilt University Medical Center, Nashville, TN, USA., Cataldo PA; University of Vermont, Burlington, VT, USA., Marcet JE; Tampa General Hospital, Tampa, FL, USA., Medich DS; University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Johnson CS; St Francis Hospital, Tulsa, OK, USA., Oommen SC; John Muir Medical Center, Concord, CA, USA., Wolff BG; Mayo Clinic, Rochester, MN, USA., Pigazzi A; University of California, Irvine, Irvine, CA, USA., McNevin SM; Holy Family Hospital, Spokane, WA, USA., Pons RK; Hialeah Hospital, Hialeah, FL, USA., Bleday R; Brigham and Women's Hospital, Boston, MA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2015 Nov; Vol. 16 (15), pp. 1537-1546. Date of Electronic Publication: 2015 Oct 22.